New trade deal pushes UK to increase drug spending to avoid Trump tariffs

The United States and the United Kingdom announced a high-level trade deal Monday that would exempt U.K. pharmaceuticals from ...
PharmiWeb

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...

Targeted Drugs for Allergic Diseases Market Set to Hit USD 30.22 Billion by 2034, Driven by Rising Allergic Disorders

The global targeted drugs for allergic diseases market size was valued at USD 13.96 billion in 2024 and is predicted to hit ...
The Manila Times

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...
BioPharma Dive

With $130M, Protego pushes forward a new type of amyloidosis drug

The startup’s lead prospect stabilizes abnormal proteins in patients with amyloid “light chain” amyloidosis, an approach that ...

Somerville biotech says its AI-created asthma drug will enter late-stage trials

There's been a lot of talk about using artificial intelligence in drug development over the past year. Now, it’s a lot closer ...
Pharmabiz

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...